Wolfram syndrome and diabetes mellitus in Aotearoa, New Zealand: Phenotype and response to GLP ‐1 receptor agonist therapy
Diabetic Medicine · 2026
DOI: 10.1111/dme.70405 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetic Medicine, 2026. Verfasst von Abigail L'Amie und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Greenlane Clinical Centre, Auckland Te Whatu Ora- Health, Auckland, New Zealand. Hauptthemen laut MEDLINE: Wolfram Syndrome, Glucagon-Like Peptide-1 Receptor Agonists, Membrane Proteins, Hypoglycemic Agents. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To describe the clinical characteristics of patients with Wolfram syndrome (WFS) and diabetes mellitus (DM) in Aotearoa, New Zealand. Review of response to therapy in those treated with glucagon‐like peptide‐1 receptor agonists (GLP1RA).
Methods
This retrospective cohort study describes 7 patients with WFS1 genetic variants (1 patient with WFS‐like syndrome), and DM from 5 New Zealand families (age range 5–33 years, 4 females, 3 males). All are receiving insulin. In 5 patients receiving GLP1RA therapy, we described their pre‐ and post‐treatment biometric parameters, glycaemic control and visual acuity.
Results
Genetic testing identified compound heterozygous variants in the WFS1 gene (inherited from each parent) in five patients. Another two were heterozygous carriers of a single WFS1 missense variant, one of which was associated with uniparental disomy. Among patients receiving GLP1RA therapy, reductions were seen in HbA1c (mean 11.6 mmol/mol) and total daily insulin dose (mean 0.25 units/kg/day).
Conclusions
We report genotypic and phenotypic variability in association with clinical features, including age of onset and severity. GLP1RA therapy was associated with improvements in diabetic control. Longer‐term follow‐up is required to monitor for sustained benefit and for progression or improvement in other WFS clinical features.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Greenlane Clinical Centre, Auckland Te Whatu Ora- Health, Auckland, New Zealand.
- Department of Endocrinology, Te Whatu Ora Waitematā, Health New Zealand, Auckland, New Zealand.
- Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
- Ophthalmology, Greenlane Clinical Centre, Auckland, Te Whatu Ora- Health New Zealand, Auckland, New Zealand.
- Starship Children's Health, Te Whatu Ora, Health New Zealand, Auckland, New Zealand.
- Liggins Institute, University of Auckland, Auckland, New Zealand.
ORCID-Profile: Abigail L'Amie, Craig A Jefferies
Zitieren
APA
L'Amie, A., Vincent, A. L., Jefferies, C. A., Braatvedt, G., Wiltshire, E., Mouat, F., Albert, B. B., & Murphy, R. (2026). Wolfram syndrome and diabetes mellitus in Aotearoa, New Zealand: Phenotype and response to GLP ‐1 receptor agonist therapy. Diabetic Medicine. https://doi.org/10.1111/dme.70405
Vancouver
L'Amie A, Vincent AL, Jefferies CA, Braatvedt G, Wiltshire E, Mouat F, et al. Wolfram syndrome and diabetes mellitus in Aotearoa, New Zealand: Phenotype and response to GLP ‐1 receptor agonist therapy. Diabetic Medicine. 2026. doi:10.1111/dme.70405
BibTeX
@article{LAmie2026,
author = {L'Amie, Abigail and Vincent, Andrea L and Jefferies, Craig A and Braatvedt, Geoffrey and Wiltshire, Esko and Mouat, Fran and Albert, Benjamin B and Murphy, Rinki},
title = {Wolfram syndrome and diabetes mellitus in Aotearoa, New Zealand: Phenotype and response to GLP ‐1 receptor agonist therapy},
journal = {Diabetic Medicine},
year = {2026},
doi = {10.1111/dme.70405}
}
EUVIMED